What can we learn from Pfizer? The recent history of the top management at Pfizer raises some interesting issues, two of which are of particular interest to me.
Thinking creative. Pfizer’s Lipitor, its cholesterol-lowering treatment, is a phenomenal success, so big that as early as 2005 it was generating 25 per cent of Pfizer’s revenues, over $12 billion per year.
Investing in future winners. As an investor in small, start-up creative businesses, I am always interested to learn about other lesser known companies around the world that are attracting interest.
Where the action is everywhere. Or there is Face.com, created in Tel Aviv, which can identify faces in photographs regardless of whether or not they’re square on to the camera.
Where the action is. Silicon Valley is not the only place to be these days when it comes to tech-based start ups.
